CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
CorMedix Therapeutics (Nasdaq: CRMD) announced that Chairman and CEO Joseph Todisco will deliver a corporate overview at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CorMedix Therapeutics (Nasdaq: CRMD) announced that Chairman and CEO Joseph Todisco will deliver a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Monday, January 12, 2026 at 4:30pm PST in presentation format and will be available via webcast.
Details
News Market Reaction – CRMD
On Jan 9, the day this news came out, CRMD closed 1.60% above the previous close.
Data tracked by StockTitan Argus for the Jan 9 session.
Key Figures
- Conference date
- January 12, 2026
- J.P. Morgan Healthcare Conference presentation date
- Presentation time
- 4:30pm PST
- Scheduled corporate overview session
- Conference edition
- 44th annual
- J.P. Morgan Healthcare Conference iteration
- Current price
- $7.51
- Pre-news close for CRMD
- 1-day change
- -32.77%
- Price change over prior 24 hours
- 52-week range
- $5.60–$17.43
- Low to high prior to this news
- S-3ASR shares
- 6,323,833 shares
- Registered for resale by existing holders
- Legal fees
- $140,000
- S-3ASR related legal expenses
Historical Context
-
Interim real-world DefenCath data showing large CRBSI and hospitalization reductions.
-
Talphera financing led by CorMedix and progress on NEPHRO CRRT study timelines.
-
Profitable Q3 with higher DefenCath use, Melinta contribution, and raised FY guidance.
-
Announcement of upcoming Q3 results call and pipeline/commercialization overview.
-
Vizient Innovative Technology designation for DefenCath highlighting clinical benefit.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BERKELEY HEIGHTS, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that Joseph Todisco, Chairman and CEO of CorMedix Therapeutics, will present a corporate overview at the 44th annual J.P. Morgan Healthcare Conference. The presentation is scheduled to take place on Monday, January 12, 2026 at 4:30pm PST.
44th Annual J.P. Morgan Healthcare Conference
| Date: | Monday, January 12, 2026 |
| Time: | 4:30pm PST |
| Format: | Presentation |
| Webcast: | Link |
About CorMedix
CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializing DefenCath® (taurolidine and heparin) for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis via a central venous catheter. Following its August 2025 acquisition of Melinta Therapeutics LLC, CorMedix is also commercializing a portfolio of anti-infective products, including MINOCIN® (minocycline) for Injection, REZZAYO® (rezafungin for injection), VABOMERE® (meropenem and vaborbactam), ORBACTIV™ (oritavancin), BAXDELA® (delafloxacin), and KIMYRSA® (oritavancin), as well as TOPROL-XL® (metoprolol succinate).
CorMedix has ongoing clinical studies for DefenCath in Total Parenteral Nutrition (TPN) and Pediatric Hemodialysis populations and also intends to develop DefenCath as a catheter lock solution for use in other patient populations. REZZAYO is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of IFD in adult patients undergoing allogeneic BMT. Topline results of the Phase III study for REZZAYO are expected in Q2 2026. For more information visit: www.cormedix.com or www.melinta.com.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.